MINNEAPOLIS - A federal judge in Minnesota on Sept. 30 issued an order of final approval to a $40 million settlement for class claims brought by third-party payers against the maker of Paxil for sales of the antidepressant to patients under 18 and handed down a separate order awarding plaintiffs' attorneys $13.3 million in fees (Carpenters and Joiners Welfare Fund, et al. v. SmithKline Beecham Corp., doing business as GlaxoSmithKline, No. CV 04-3500, D. Minn.). From Mealey's Emerging Drugs & Devices